2146 Results

People

  1. Aghajanian
    Aghajanian
  2. Hensley
    Hensley
  3. Abu-Rustum
    Abu-Rustum
  4. O'Cearbhaill
    O'Cearbhaill
  5. Makker
    Makker
  6. Tew
    Tew
  7. Lichtman
    Lichtman
  8. Zamarin
    Zamarin
  9. Chi
    Chi
  10. Iasonos
    Iasonos

Groups

  1. Gynecologic Medicine Service (2146)
  2. Solid Tumor Oncology Division (2146)
  3. Department of Medicine (2142)
  4. Gynecology Disease Management Team (1846)
  5. GDMT, Medicine (1828)
  6. Surgery (594)
  7. GDMT, Surgery (474)
  8. Epidemiology and Biostatistics (398)
  9. Department of Pathology and Laboratory Medicine (395)
  10. Survivorship Research (390)
  1. "Gynecologic Medicine Service"
Formats
  1. Journal Article (1087)
  2. Meeting Abstract (890)
  3. Review (52)
  4. Book Section (46)
  5. Editorial (35)
  6. Guidelines (21)
  7. Correspondence (9)
  8. Miscellaneous (3)
  9. Research Letter (2)
  10. Book Whole (1)
Groups
  1. Gynecologic Medicine Service (2146)
  2. Solid Tumor Oncology Division (2146)
  3. Department of Medicine (2142)
  4. Gynecology Disease Management Team (1846)
  5. GDMT, Medicine (1828)
  6. Surgery (594)

More Groups

People
  1. Carol Aghajanian (607)
  2. Martee Hensley (289)
  3. Nadeem Abu-Rustum (288)
  4. Roisin O'Cearbhaill (271)
  5. Vicky Makker (263)
  6. Paul Sabbatini (262)

More People

Years
  1. 2025 (41)
  2. 2024 (167)
  3. 2023 (171)
  4. 2022 (209)
  5. 2021 (163)
  6. 2020 (203)

More Years

Publications
  1. Journal of Clinical Oncology (450)
  2. Gynecologic Oncology (418)
  3. International Journal of Gynecological Cancer (154)
  4. Annals of Oncology (116)
  5. Clinical Cancer Research (67)
  6. Cancer Research (55)

More Publications

Publishers
  1. Elsevier Inc. (542)
  2. American Society of Clinical Oncology (489)
  3. Lippincott Williams & Wilkins (181)
  4. American Association for Cancer Research (168)
  5. Oxford University Press (143)
  6. Nature Publishing Group (86)

More Publishers

Results (2146)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • Germline SMARCA4 deletion as a driver of uterine cancer: An atypical presentation
    Journal Article

    Navitski, A.; Al-Rawi, D. H.; Makker, V.; Weigelt, B.; Zamarin, D.; Liu, Y.; Arnold, A. G.; Chui, M. H.; Mandelker, D. L.; Walsh, M.; more...
    JCO Precision Oncology (2022)

    Fulltext@MSK | Save
  • Risk stratification of stage I grade 3 endometrioid endometrial carcinoma in the era of molecular classification
    Journal Article

    Zammarrelli, W. A. 3rd; Kim, S. H.; Da Cruz Paula, A.; Rios-Doria, E. V.; Ehmann, S.; Yeoshoua, E.; Hanlon, E. J.; Zhou, Q.; Iasonos, A.; Alektiar, K. M.; more...
    JCO Precision Oncology (2022)

    Fulltext@MSK | Save
  • MEDI1191 (IL-12 MRNA) induces peripheral and intratumoral immunostimulatory effect in patients with cutaneous or subcutaneous (c/sc) lesions
    Meeting Abstract

    Abadier, M.; Jennings, E.; Eyles, J.; Martin, P.; Pilataxi, F.; Wu, Y.; Chen, X.; Azaro, A.; Ridgway, B.; Phillips, M.; more...
    Journal for ImmunoTherapy of Cancer (2022)

    Fulltext@MSK | Save
  • Phase 1/2a study of the novel nonfucosylated anti–CTLA-4 monoclonal antibody BMS-986218 ± nivolumab in advanced solid tumors: Part 1 results
    Meeting Abstract

    Friedman, C.; Carvajal, R.; Davar, D.; Castanon, E.; Ascierto, P.; Calvo, E.; O'Hara, M.; Powell, S.; Shapira-Frommer, R.; Garralda, E.; more...
    Journal for ImmunoTherapy of Cancer (2022)

    Fulltext@MSK | Save
  • PETRA: First in class, first in human trial of the next generation PARP1-selective inhibitor AZD5305 in patients (pts) with BRCA1/2, PALB2 or RAD51C/D mutations
    Meeting Abstract

    Yap, T. A.; Im, S. A.; Schram, A. M.; Sharp, A.; Balmana, J.; Baird, R. D.; Brown, J. S.; Schwaederle, M.; Pilling, E. A.; Moorthy, G.; more...
    Cancer Research (2022)

    Fulltext@MSK | Save
  • Ceralasertib and olaparib in the treatment of homologous recombination repair (HRR)-deficient platinum-sensitive ovarian cancer after progression on PARP inhibitors
    Meeting Abstract

    Shapiro, G. I.; Basu, B.; El-Khoueiry, A.; Postel-Vinay, S.; Im, S. A.; Rha, S. Y.; Friedman, C. F.; Italiano, A.; Kim, Y. M.; Lim, M. C.; more...
    Cancer Research (2022)

    Fulltext@MSK | Save
  • A phase 1a/1b study of STK-012, an α/β IL-2 receptor selective partial agonist as monotherapy and in combination with pembrolizumab in advanced solid tumors (NCT05098132)
    Meeting Abstract

    Spigel, D.; Spira, A.; Zamarin, D.; McDermott, D. F.; Luke, J.; Heymach, J. V.; Previs, R.; Sullivan, R.; Gandhi, L.; Azrilevich, A.; more...
    Cancer Research (2022)

    Fulltext@MSK | Save
  • First-in-human study of MEDI1191 (mRNA encoding IL-12) plus durvalumab in patients (pts) with advanced solid tumors
    Meeting Abstract

    Carneiro, B. A.; Zamarin, D.; Marron, T.; Mehmi, I.; Patel, S. P.; Subbiah, V.; El-Khoueiry, A.; Grand, D.; Garcia-Reyes, K.; Goel, S.; more...
    Cancer Research (2022)

    Fulltext@MSK | Save
  • First-in-human trial of intravenous MEDI9253, an oncolytic virus, in combination with durvalumab in patients with advanced solid tumors
    Meeting Abstract

    Purroy, N.; Durham, N.; Phillips, M.; Hattersley, M. M.; Jung, L.; Davar, D.; Zamarin, D.; Johanns, T. M.; Puzanov, I.
    Cancer Research (2022)

    Fulltext@MSK | Save
  • Optimization of shared neoantigen vaccine design to increase vaccine potency: From bench to bedside and back
    Meeting Abstract

    Rappaport, A. R.; Palmer, C. D.; Shen, A.; Dominguez, C. X.; Hart, M. G.; Kraemer, L. D.; Koulavouth, S.; Marrali, M.; Jaroslavsky, J. R.; Nganje, C. N.; more...
    Cancer Research (2022)

    Fulltext@MSK | Save